
Opinion|Videos|June 28, 2024
Review of MOA and Effectiveness of Current Treatments
Hematologic oncologists review therapeutic options for patients with chronic GVHD and provide clinical insights on their treatment approaches.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Please discuss the effectiveness of the most used systemic treatment options.
- How do you sequence treatments for chronic GVHD?
- What are the most pressing challenges faced by healthcare providers in effectively managing cGVHD, particularly in patients who have progressed through multiple treatment lines?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5












































